PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Poly(ADP-ribose) polymerase (PARP) enzymes are crucial for DNA repair pathways, particularly single-strand DNA break base excision repair.
• PARP inhibition exploits synthetic lethality in cancers with homologous recombination deficiency, such as those with BRCA1/BRCA2 mutations.

Purpose of the Study:

• To review the role of PARP inhibitors in breast cancer treatment.
• To explore the potential benefits of PARP inhibitors in triple-negative breast cancer (TNBC) with wild-type BRCA.
• To identify future research directions for PARP inhibitor therapy.

Main Methods:

• Literature review of clinical trials and translational research on PARP inhibitors in breast cancer.
• Analysis of efficacy data for PARP inhibitors in different breast cancer subtypes.
• Discussion of mechanisms of action and resistance.

Main Results:

• PARP inhibitors are established treatments for metastatic breast cancer with germline BRCA1/BRCA2 mutations.
• Patients with homologous recombination deficiency (BRCAness), including some TNBC cases, may benefit from PARP inhibition.
• Current efficacy of PARP inhibitors in TNBC with wild-type BRCA is not definitive, highlighting an area for further investigation.

Conclusions:

• PARP inhibitors offer a targeted therapy for specific breast cancer populations, particularly those with BRCA mutations.
• Expanding the use of PARP inhibitors to TNBC with wild-type BRCA requires further clinical and translational research.
• Identifying novel biomarkers and patient subgroups may broaden the application of PARP inhibitor therapy.